Closing Remarks on Upcoming Data and Future Perspectives in MCL and CLL
Looking to the future, a panel of experts offers closing remarks on research in CLL and MCL including hopes for further data on bispecific antibodies, BTK degraders, CAR T-cell therapy, and pirtobrutinib.
Pirtobrutinib and Other Non-Covalent BTK Inhibitors in the Treatment of CLL
The assembled faculty comment on data on the role of non-covalent BTK inhibitors in the CLL treatment landscape, with emphasis on the phase 1/2 BRUIN trial of pirtobrutinib.
Anti-CD20 Regimens and Triplet Therapies in CLL
Orienting the conversation around anti-CD20-drug-based combination and sequencing approaches, the panelists examine key takeaways from the CLL13 and CLL14 clinical trials as well as expectations for real-world data in the future.
Considerations for COVID-19 in MCL and CLL
Focusing the discussion on the current state of the COVID-19 pandemic, Catherine C. Coombs, MD, shares key insights into the use of COVID-19 pre-exposure prevention for patients with CLL or MCL.
The Potential Role of Venetoclax Combination Approaches in CLL
Experts in hematologic malignancies reflect on clinical trials studying venetoclax combination approaches including the CAPTIVATE, FLAIR, GLOW, VISION, SEQUOIA, and MAJIC studies.
TRANSCEND CLL: CAR T-cell Therapy for CLL
Panelists respond to a question from Michael Wang, MD, about the role of CAR T-cell therapy in CLL, and Brian T. Hill, MD, PhD, summarizes takeaways from the TRANSCEND CLL study.
Emerging Approaches in CLL
The faculty members share expert insights into treatment approaches for patients with double-refractory chronic lymphocytic leukemia.
Updates from Patient-reported QOL and Matching-adjusted Indirect Treatment Comparisons (MAICs) Studies in CLL
Brian T. Hill, MD, PhD, and Matthew S. Davids, MD, MMSc, address the role of study design in CLL to highlight the importance of patient-reported QOL outcomes and matching-adjusted indirect treatment comparisons (MAICs).
Dr. Mato on Factors for Choosing BTK Inhibitors or Venetoclax in CLL
Anthony Mato, MD, MSCE, discusses the factors used to make treatment decisions between BTK inhibitors and venetoclax in chronic lymphocytic leukemia.
Treatment Decision-making Among Second-generation BTKis in CLL
Key opinion leaders in CLL review factors driving therapeutic decision-making among the available second-generation BTK inhibitors including efficacy and safety considerations.
Zanubrutinib in CLL: The ALPINE Trial
An expert in hematologic malignancies, Catherine C. Coombs, MD, shares insights gleaned from the ALPINE clinical trial of zanubrutinib vs ibrutinib for relapsed/refractory CLL.
Acalabrutinib in CLL: Insights from the ELEVATE TN and ASCEND Trials
Highlighting the ELEVATE TN and ASCEND clinical trials, panelists share expert insights into the next-generation BTK inhibitor acalabrutinib for CLL.
Treatment Overview: Chronic Lymphocytic Leukemia
Catherine C. Coombs, MD, leads the faculty in a discussion of the current treatment landscape for CLL with a review of considerations for patients with high-risk or relapsed/refractory disease.
Advancements on the Horizon in Mantle Cell Lymphoma
Thought leaders in hematologic malignancies reflect on studies of ROR1 and share perspectives on advancements on the horizon for mantle cell lymphoma.
Strategies for Sequencing and Combining Therapies in MCL
A panel of distinguished faculty builds a lively conversation on the emergence of pirtobrutinib and its effect on treatment sequencing strategies in MCL as well as the overall role of doublet and triplet regimens.
CAR T-Cell Therapy in R/R MCL
Michael Wang, MD, guides the panel in a discussion on CAR T-cell therapy for relapsed/refractory MCL including a summary of key takeaways from the ZUMA-2 trial and a conversation on real-world vs clinical trial data.
BTK Inhibitors in Relapsed/Refractory MCL and Treatment Selection
Panelists discuss treatment considerations in the use of BTK inhibitors for relapsed/refractory mantle cell lymphoma, with Matthew S. Davids, MD, MMSc, reviewing strategies for the management of AEs.
Second-line Therapies in MCL: Regimens With BTK Inhibitors and BCL-2 Targeting Therapies
Key opinion leaders in mantle cell lymphoma discuss the emergence of more effective novel therapies such as BTK inhibitors and BCL-2 inhibitors and whether there is a continued role for lenalidomide-based regimens.
Mantle Cell Lymphoma Maintenance Strategies
A panel of experts in hematologic malignancies discusses maintenance strategies for mantle cell lymphoma with particular emphasis on treatment considerations related to the COVID-19 pandemic and real-world data.
Factors for Consideration in Treatment Decision-making for MCL
Focusing on the differences in treatment considerations between younger and older patients, Michael Wang, MD, discusses the current treatment landscape in mantle cell lymphoma.
Disease Overview: Mantle Cell Lymphoma
Anthony R. Mato, MD, MSCE, introduces the panel, and Alexey V. Danilov, MD, PhD, provides an overview of the incidence, presentation, pathologic features, and treatment landscape for mantle cell lymphoma.
Optimizing the Treatment of CLL With Novel Therapies
Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.
CAR T-Cell Therapies in CLL
Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.
PI3K Inhibitors for CLL
A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.
Novel Therapies for CLL: Sequencing Strategies
Factors that impact decisions for frontline and subsequent lines of therapy for patients with chronic lymphocytic leukemia.
Chemotherapy-Free Regimens as Frontline Therapy in CLL
Key takeaways of the CLL13 (GAIA) clinical trial based on highlights presented at ASH 2021.
Fixed-Duration Therapy in Relapsed/Refractory CLL: Ibrutinib Plus Venetoclax
Considerations for treating patients with relapsed/refractory chronic lymphocytic leukemia with the combination of ibrutinib and venetoclax.
Fixed-Duration Therapy in Frontline CLL: Venetoclax Plus Obinutuzumab
The rationale for investigating the fixed-duration, all-oral combination regimen of venetoclax with obinutuzumab as treatment for chronic lymphocytic leukemia.
Fixed-Duration Therapy in Frontline CLL: Ibrutinib Plus Venetoclax
Key takeaways from the CAPTIVATE and GLOW trials of ibrutinib plus venetoclax as fixed-duration frontline therapy for chronic lymphocytic leukemia.
Frontline Therapy for CLL: Treatment Selection Based on Patient and Treatment Factors
Variables that impact which Bruton tyrosine kinase inhibitor is most appropriate as frontline therapy for patients with newly diagnosed chronic lymphocytic leukemia and the role of patient and disease factors in treatment selection.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512